A Nationwide Survey of the Seroprevalence of Hepatitis E Virus Infections Among Blood Donors in Thailand
Viral Immunology, Ahead of Print.
Publication date: Available online 12 December 2019Source: Journal of the Formosan Medical AssociationAuthor(s): Chien-Lin Chen, Wei-Chuan Chang, Ching-Sheng Hsu
Publication date: Available online 12 December 2019Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Jean-Pierre Zarski, Sandra David-Tchouda, Candice Trocme, Jennifer Margier, Antoine Vilotitch, Marie-Noelle Hilleret, Carole Cagnot, Valerie Boursier, Marianne Ziol, Angela Sutton, Richard Layese, Etienne Audureau, Francoise Roudot-Thoraval, Pierre NahonSummaryBackground and AimsMarkers predicting complications of post-hepatitis C cirrhosis are needed. We asked whether changes in noninvasive markers of fibrosis can predict liver-related complications.MethodsThis was a case-controlled study using a pr...
Publication date: Available online 12 December 2019Source: Prostaglandins &Other Lipid MediatorsAuthor(s): Rodolfo Quintana Castro, Isaac Aguirre Maldonado, Ida Soto Rodríguez, Rosa A. Deschamps Lago, Peter Grube Pagola, Yolanda K. Urbina de Larrea, Victoria E. Juárez Rivera, Luis E. Ramos Manuel, Alfonso Alexander AguileraAbstractObesity is considered a global epidemic and is mainly associated with the development of diabetes, cardiovascular diseases and Non-Alcoholic Fatty Liver (NAFLD). The pathogenesis between obesity and hepatic steatosis is partially known, but could involve differentiated or tissue...
Foodborne Pathogens and Disease, Ahead of Print.
ConclusionsShort-term use of pradefovir was well tolerated. A decline in HBV DNA levels was superior to TDF at higher doses of pradefovir. 30–60 mg pradefovir is recommended for CHB treatment.Clinical trial numberCTR20150224.
Conclusions: The number of agreements and the allocated budget subject to these agreements increased substantially in recent years. Most agreements are financial-based that, in many cases, shifted the short-term financial risk from health-plans to the industry. PMID: 31825682 [PubMed - as supplied by publisher]
ConclusionsThis real-word experience study confirmed similar, high effectiveness of 8 and 12-weeks regimens of OPrD in genotype 1b HCV infected patients with non-advanced fibrosis. Despite of reduced SVR rate after 8-weeks regimen, there is no need to extend therapy to 12-weeks in vast majority of such patients and no need to add ribavirin.
Elecsys Anti-HAV IgM assay-for the in vitro qualitative detection of IgM antibodies to hepatitis A virus (anti-HAV IgM) in human serum and plasma Catalog number: 07026773190
Leukemia, Published online: 13 December 2019; doi:10.1038/s41375-019-0687-2Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection
In this study, we found the levels of HBV RNA, DNA, and core and envelope proteins to be significantly downregulated by SEL1L overexpression and upregulated by SEL1L silencing in Huh7 cells transiently transfected with an overlength HBV genome. Similar upregulation was observed in HepG2.2.15 cells as well. SEL1L co-localized with HBV surface antigen (HBsAg), which changed its staining pattern. Treatment with an inhibitor of ERAD pathway remarkably increased intracellular S protein. Surprisingly, silencing SEL1L to block the ERAD pathway activated an alternative ER quality control (ERQC)-autophagy pathway, which might accou...